134 related articles for article (PubMed ID: 16766190)
1. QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Duchowicz PR; Fernández M; Caballero J; Castro EA; Fernández FM
Bioorg Med Chem; 2006 Sep; 14(17):5876-89. PubMed ID: 16766190
[TBL] [Abstract][Full Text] [Related]
2. 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors.
Cocuzza AJ; Chidester DR; Cordova BC; Klabe RM; Jeffrey S; Diamond S; Weigelt CA; Ko SS; Bacheler LT; Erickson-Viitanen SK; Rodgers JD
Bioorg Med Chem Lett; 2001 Jun; 11(11):1389-92. PubMed ID: 11378361
[TBL] [Abstract][Full Text] [Related]
3. Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives.
Pungpo P; Saparpakorn P; Wolschann P; Hannongbua S
SAR QSAR Environ Res; 2006 Aug; 17(4):353-70. PubMed ID: 16920659
[TBL] [Abstract][Full Text] [Related]
4. In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Gianotti N; Boeri E; Maillard M; Serra G; Ratti D; Gallotta G; Vacchini D; Tremolada Y; Castagna A
New Microbiol; 2004 Apr; 27(2 Suppl 1):111-7. PubMed ID: 15646073
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
Corbett JW; Ko SS; Rodgers JD; Gearhart LA; Magnus NA; Bacheler LT; Diamond S; Jeffrey S; Klabe RM; Cordova BC; Garber S; Logue K; Trainor GL; Anderson PS; Erickson-Viitanen SK
J Med Chem; 2000 May; 43(10):2019-30. PubMed ID: 10821714
[TBL] [Abstract][Full Text] [Related]
6. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
[TBL] [Abstract][Full Text] [Related]
7. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
Rodríguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
8. Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors.
Geitmann M; Unge T; Danielson UH
J Med Chem; 2006 Apr; 49(8):2367-74. PubMed ID: 16610780
[TBL] [Abstract][Full Text] [Related]
9. Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues.
Udier-Blagović M; Tirado-Rives J; Jorgensen WL
J Med Chem; 2004 Apr; 47(9):2389-92. PubMed ID: 15084137
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
[TBL] [Abstract][Full Text] [Related]
11. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
[TBL] [Abstract][Full Text] [Related]
12. [Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Zhou T; Xie L
Yao Xue Xue Bao; 2004 Aug; 39(8):666-72. PubMed ID: 15563074
[No Abstract] [Full Text] [Related]
13. Classification and regression trees--studies of HIV reverse transcriptase inhibitors.
Daszykowski M; Walczak B; Xu QS; Daeyaert F; de Jonge MR; Heeres J; Koymans LM; Lewi PJ; Vinkers HM; Janssen PA; Massart DL
J Chem Inf Comput Sci; 2004; 44(2):716-26. PubMed ID: 15032554
[TBL] [Abstract][Full Text] [Related]
14. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
Ragno R; Artico M; De Martino G; La Regina G; Coluccia A; Di Pasquali A; Silvestri R
J Med Chem; 2005 Jan; 48(1):213-23. PubMed ID: 15634015
[TBL] [Abstract][Full Text] [Related]
15. 4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
Benjahad A; Courté K; Guillemont J; Mabire D; Coupa S; Poncelet A; Csoka I; Andries K; Pauwels R; de Béthune MP; Monneret C; Bisagni E; Nguyen CH; Grierson DS
J Med Chem; 2004 Oct; 47(22):5501-14. PubMed ID: 15481987
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
San Juan AA
Bioorg Med Chem Lett; 2008 Feb; 18(3):1181-94. PubMed ID: 18155520
[TBL] [Abstract][Full Text] [Related]
17. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
[TBL] [Abstract][Full Text] [Related]
18. QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors.
Balaji S; Karthikeyan C; Moorthy NS; Trivedi P
Bioorg Med Chem Lett; 2004 Dec; 14(24):6089-94. PubMed ID: 15546736
[TBL] [Abstract][Full Text] [Related]
19. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
Liang YH; He QQ; Zeng ZS; Liu ZQ; Feng XQ; Chen FE; Balzarini J; Pannecouque C; Clercq ED
Bioorg Med Chem; 2010 Jul; 18(13):4601-5. PubMed ID: 20570527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
